Document is current
Any future updates will be listed below
-
Authors
Garcia-Marquez, Maria A. http://orcid.org/0000-0002-5923-5942
Thelen, Martin http://orcid.org/0000-0002-2785-9726
Reinke, Sarah
Keller, Diandra
Wennhold, Kerstin
Lehmann, Jonas
Veldman, Johanna http://orcid.org/0000-0003-4253-0870
Borchmann, Sven
Rosenwald, Andreas
Sasse, Stephanie
Diepstra, Arjan http://orcid.org/0000-0001-9239-1050
Borchmann, Peter
Engert, Andreas
Klapper, Wolfram http://orcid.org/0000-0001-7208-4117
von Bergwelt-Baildon, Michael
Bröckelmann, Paul J. http://orcid.org/0000-0001-9662-9900
Schlößer, Hans A.
-
Funding
Funding for this research was provided by:
Deutsche Krebshilfe (70112502, 70113307, 70113702)
Deutsche Forschungsgemeinschaft (325827080)
Career Advancement Program (CAP) of the Center for Molecular Medicine Cologne
- License Information
-
More Information
Article History
Received: 13 June 2021
Revised: 6 September 2021
Accepted: 8 September 2021
First Online: 28 September 2021
Competing interests
: SB: Founder, CEO and shareholder of Liqomics, personal fees and non-financial support from Bristol-Myers Squibb and Takeda; AD Financial support for research projects from Takeda; WK Research grants from Regeneron, Amgen, Roche and Takeda; MBB: Honoraria for advisory boards, for invited talks from BMS and financial support for research projects from Astellas, Roche and MSD; PJB: Research grants from BeiGene, Bristol Myers Squibb, Merck Sharpe & Dohme, and Takeda; and personal fees and non-financial support from Bristol-Myers Squibb, Celgene and Takeda; HAS: Financial support for research projects from Astra Zeneca. All reported COIs are outside the submitted work and all other authors declare no potential conflicts of interest.
